2950-5909

CMI Communications

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 182 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact182 DOIs
2

Attach ORCID iDs across 66 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact66 DOIs
3

Deposit reference lists for 15 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact15 DOIs

DOIs for this ISSN

Showing the top 5 of 182 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 ESCMID Global Abstract Book 2025 (10.1016/j.cmicom.2025.105086)
Abstract References ORCID
58.36 5
2 Tetracyclines, the old and the new: A narrative review (10.1016/j.cmicom.2025.105059)
Abstract
43.11 52
3 Molecular epidemiology of invasive Group A streptococcal inf… (10.1016/j.cmicom.2024.100004)
Abstract ORCID
42.25 6
4 Message from the Editor-in-Chief (10.1016/j.cmicom.2024.100001)
Abstract ORCID
38.91 5
5 ESCMID Global Abstract Book 2024 (10.1016/j.cmicom.2024.100013)
Abstract References ORCID
35.78 2
6 Universal access to key essential antibiotics—Recent amoxici… (10.1016/j.cmicom.2024.105035)
Abstract
30.10 15
7 Approach to melioidosis (10.1016/j.cmicom.2024.100008)
Abstract
28.65 13
8 Risk factors associated with bloodstream infections caused b… (10.1016/j.cmicom.2025.105060)
Abstract
26.03 10
9 Rationale for contemporary antimicrobial treatment of Stenot… (10.1016/j.cmicom.2025.105082)
Abstract
26.03 10
10 Current management strategies for multidrug-resistant Gram-n… (10.1016/j.cmicom.2024.105039)
Abstract
25.00 9
11 How to establish a hospital wastewater surveillance program… (10.1016/j.cmicom.2025.105087)
Abstract
23.86 8
12 Joining the X-odus: Contrasting perspectives on whether infe… (10.1016/j.cmicom.2025.105140)
Abstract ORCID
23.86 2
13 ECCMID is now ESCMID Global (10.1016/j.cmicom.2024.105011)
Abstract References ORCID
22.58 1
14 The long-term sustainability of a pharmacist-led antimicrobi… (10.1016/j.cmicom.2024.105055)
Abstract
22.58 7
15 Communicable episode 37: ‘Peer review is broken’ (10.1016/j.cmicom.2025.105164)
Abstract References ORCID
22.58 1
16 Imported severe West Nile virus neuro-invasive disease treat… (10.1016/j.cmicom.2024.105034)
Abstract
21.13 6
17 Hospital cleaning: considerations for designing and maintain… (10.1016/j.cmicom.2025.105102)
Abstract
21.13 6
18 (Val)ganciclovir dosing for cytomegalovirus: revisiting the… (10.1016/j.cmicom.2025.105171)
Abstract
21.13 6
19 Diagnostic tests should be assessed for clinical impact (10.1016/j.cmicom.2024.105010)
Abstract
19.45 5
20 Selective digestive tract decontamination in the intensive c… (10.1016/j.cmicom.2025.105078)
Abstract
19.45 5
21 Phage research in South America: A descriptive overview of t… (10.1016/j.cmicom.2025.105135)
Abstract
19.45 5
22 Antibiotics’ collateral effects on the gut microbiota in the… (10.1016/j.cmicom.2024.100012)
Abstract
17.47 4
23 Partial oral treatment of infective endocarditis in real-wor… (10.1016/j.cmicom.2024.105032)
Abstract
17.47 4
24 A global call to action to fight antimicrobial resistance: I… (10.1016/j.cmicom.2024.105033)
Abstract
17.47 4
25 Early oral switch therapy for infective endocarditis: An int… (10.1016/j.cmicom.2025.105063)
Abstract
17.47 4
26 Cefepime trough levels and clinical outcomes in patients und… (10.1016/j.cmicom.2024.100011)
Abstract
15.05 3
27 Examining hypoglycemia risk with systemic fluoroquinolone us… (10.1016/j.cmicom.2024.105038)
Abstract
15.05 3
28 Oral vancomycin prophylaxis for the prevention of recurrent… (10.1016/j.cmicom.2024.105041)
Abstract
15.05 3
29 Communicable Episode 04: The BLING III trial & continuou… (10.1016/j.cmicom.2024.105046)
Abstract ORCID
15.05 1
30 Resistance Optimised Antibiotic Dosing (The ROAD Study): Is… (10.1016/j.cmicom.2024.105051)
Abstract
15.05 3
31 Communicable Episode 09: An update on avian flu (10.1016/j.cmicom.2024.105052)
Abstract ORCID
15.05 1
32 Communicable Episode 10: Pipeline update on new antibiotics… (10.1016/j.cmicom.2024.105054)
Abstract ORCID
15.05 1
33 From medical editors: A call to the global infectious diseas… (10.1016/j.cmicom.2025.105062)
Abstract ORCID
15.05 1
34 Detection of Rickettsia in ticks using loop-mediated isother… (10.1016/j.cmicom.2025.105069)
Abstract ORCID
15.05 1
35 Comparison between clinical outcomes in influenza A and B In… (10.1016/j.cmicom.2025.105072)
Abstract
15.05 3
36 Short-course aminoglycosides as adjunctive treatment in adul… (10.1016/j.cmicom.2025.105075)
Abstract
15.05 3
37 Opportunities for rhinovirus-targeted RNA therapeutics: A na… (10.1016/j.cmicom.2025.105081)
Abstract
15.05 3
38 Communicable Episode 13: The Wild West of publishing today -… (10.1016/j.cmicom.2025.105089)
Abstract ORCID
15.05 1
39 Communicable Episode 16: Climate change and infections – eff… (10.1016/j.cmicom.2025.105093)
Abstract ORCID
15.05 1
40 Standing on the shoulders of Edward H. Kass (10.1016/j.cmicom.2025.105098)
Abstract ORCID
15.05 1
41 To heal or harm: A systematic review of the role of fluoroqu… (10.1016/j.cmicom.2025.105103)
Abstract
15.05 3
42 CMI Communications: An open call for editorial fellows to gr… (10.1016/j.cmicom.2025.105119)
Abstract ORCID
15.05 1
43 Breaking down the Desirability of Outcome Ranking (DOOR): un… (10.1016/j.cmicom.2025.105154)
Abstract
15.05 3
44 Communicable episode 41: Diagnostic stewardship (10.1016/j.cmicom.2026.105176)
Abstract ORCID
15.05 1
45 Clinical severity of Delta and 3 different Omicron sublineag… (10.1016/j.cmicom.2024.100005)
Abstract
11.93 2
46 Establishing a dedicated UTI clinic: Challenges and a guide… (10.1016/j.cmicom.2024.105036)
Abstract
11.93 2
47 Post-pandemic consumption of outpatient antibiotics in Switz… (10.1016/j.cmicom.2024.105037)
Abstract
11.93 2
48 Exploring desirability of outcome ranking and generalised pa… (10.1016/j.cmicom.2024.105040)
Abstract
11.93 2
49 Immunity to urinary tract infection: What the clinician shou… (10.1016/j.cmicom.2024.105057)
Abstract
11.93 2
50 Histoplasmosis and blastomycosis: Progress and possibilities (10.1016/j.cmicom.2025.105067)
Abstract
11.93 2